Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Lassen U, Miller WH, Hotte S, Evans TR, Kollmansberger C, Adamson D, Nielsen DL, Spicer J, Chen E, Meyer T, Brown K, Rafi R, Sawyer MB. Lassen U, et al. Among authors: nielsen dl. Cancer Chemother Pharmacol. 2013 Feb;71(2):543-9. doi: 10.1007/s00280-012-2038-0. Epub 2012 Nov 30. Cancer Chemother Pharmacol. 2013. PMID: 23196640 Clinical Trial.
Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics.
Kümler I, Sørensen PG, Palshof J, Høgdall E, Skovrider-Ruminski W, Theile S, Fullerton A, Nielsen PG, Jensen BV, Nielsen DL. Kümler I, et al. Among authors: nielsen dl, nielsen pg. Cancer Chemother Pharmacol. 2019 Jan;83(1):169-178. doi: 10.1007/s00280-018-3720-7. Epub 2018 Nov 8. Cancer Chemother Pharmacol. 2019. PMID: 30406838 Free PMC article. Clinical Trial.
An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine.
Kümler I, Eefsen RL, Sørensen PG, Theile S, Fullerton A, Nielsen PG, Jensen BV, Nielsen DL. Kümler I, et al. Among authors: nielsen dl, nielsen pg. Cancer Chemother Pharmacol. 2019 Aug;84(2):441-446. doi: 10.1007/s00280-019-03819-0. Epub 2019 Apr 4. Cancer Chemother Pharmacol. 2019. PMID: 30949758
Cellular resistance to anthracyclines.
Nielsen D, Maare C, Skovsgaard T. Nielsen D, et al. Gen Pharmacol. 1996 Mar;27(2):251-5. doi: 10.1016/0306-3623(95)02013-6. Gen Pharmacol. 1996. PMID: 8919638 Review.
179 results